The Oklahoma Shared Clinical and Translational Resources

The OSCTR is funded by the National Institutes of Health as part of its IDeA-CTR program. We have the mission to serve as a catalyst for clinical and translational research that improves health and healthcare for underserved and underrepresented populations, to provide training and infrastructure to help junior investigators to launch independent research careers, and to expand the opportunities of IDeA states and Oklahoma communities to participate in research that improves the health of our residents. 

Oklahoma Clinical and Translational Science Institute

 

OCTSI is the home of the OSCTR, as well as clinical research services and dissemination and implementation resources to help improve the delivery of healthcare. 

Oklahoma Primary Healthcare Improvement Cooperative

 

OPHIC is the implementation science arm of a statewide network to help improve healthcare delivery assisting primary care practices to adopt evidence-based best practices for the care of their patients.

OCTSI Clinical Research Unit

​​

The OCTSI CRU assists medical providers to identify and conduct clinical research opportunities in Oklahoma.

University of Oklahoma Health Sciences Receives Federal Funding to Improve Health Care Access Across the State

Across large areas of Oklahoma and the nation, primary care clinics are a lifeline, providing care for people who otherwise would have to travel many miles to see a doctor. To increase access to vital health care, the National Institutes of Health announced an ambitious new initiative to integrate NIH-funded clinical trials into routine patient care in medically underserved areas like rural Oklahoma and within Tribal nations.

OU Awarded $17 Million NIH Grant to Improve Cancer Outcomes Among Native Americans

The National Institutes of Health has awarded the University of Oklahoma a five-year, $17.2 million grant to partner with tribal nations and communities to improve cancer outcomes. Research has shown that the American Indian and Alaska Native population in Oklahoma experiences a 36% higher incidence of cancer and a 73% higher death rate from cancer than faced by the U.S. general population.

Plasma Exosomes Show Promise for Early Detection of Pancreatic Cancer

Pancreatic cancer is the fourth leading cause of cancer deaths in the United States, and pancreatic cancer has some of the lowest 5-year survival rates of any cancer. Early detection can improve survival rates. When pancreatic ductal adenocarcinoma is initially diagnosed at stage IV, patients have a 2.7% 5-year survival rate. When diagnosis occurs at Stage I or IIA, this improves to 34%. However, there are currently no accurate blood tests for early detection of pancreatic cancer.

ECHO Grant Awarded to OUHSC

The OCTSI has partnered with the OUHSC Department of Pediatrics and been awarded a grant from the National Institutes of Health to develop the Oklahoma Pediatric Clinical Trial Network. This network will be part of the IDeA States Pediatric Clinical Trials Network that is participating in the Environmental Impacts of Child Health Outcomes (ECHO) Program to effectively investigate the impacts of environmental exposures from the womb through later years in a child’s life. The Principal Investigator of this award is Dr. Paul Darden, Chief of General and Community Pediatrics at OUHSC.

Listening Session for AI/AN Inclusion in All of Us Program

The Southern Plains Tribal Health Board, the Oklahoma delegation from the National Institutes of Health (NIH) Tribal Advisory Committee, and the All of Us Research Program are hosting a listening session on Tuesday, October 22, 2019 in Oklahoma City, OK.

The All of Us Research Program, part of NIH, has a simple mission: to speed up health research breakthroughs and help foster an era of precision medicine for all.

What: The goals for this listening session are to:

Subscribe to News

Recent Publications

Enhancing geriatric trauma mortality prediction: Modifying and assessing the Geriatric Trauma Outcome Score with net benefit and decision curve analysis

Acad Emerg Med. 2025 Feb 6. doi: 10.1111/acem.15103. Online ahead of print.

ABSTRACT

OBJECTIVE: Calibration and discrimination indicators alone are insufficient for evaluating the clinical usefulness of prediction models, as they do not account for the cost of misclassification errors. This study aimed to modify the Geriatric Trauma Outcome Score (GTOS) and assess the clinical utility of the modified model using net benefit (NB) and decision curve analysis (DCA) for predicting in-hospital mortality.

Nirmatrelvir/Ritonavir (Paxlovid) Use Among Individuals at Risk of Severe COVID-19: An Analysis of the National COVID Cohort Collaborative (N3C)

Pharmacoepidemiol Drug Saf. 2024 Aug;33(8):e5869. doi: 10.1002/pds.5869.

ABSTRACT

PURPOSE: Paxlovid is effective in reducing COVID-19 hospitalization and mortality. This study characterized Paxlovid use and evaluated racial/ethnic disparities over time among community-dwelling adults at high risk of progression to severe COVID-19 disease.

Associations between COVID-19 therapies and outcomes in rural and urban America: A multisite, temporal analysis from the Alpha to Omicron SARS-CoV-2 variants

J Rural Health. 2024 Jul 2. doi: 10.1111/jrh.12857. Online ahead of print.

ABSTRACT

PURPOSE: To investigate the enduring disparities in adverse COVID-19 events between urban and rural communities in the United States, focusing on the effects of SARS-CoV-2 vaccination and therapeutic advances on patient outcomes.

Media

Upcoming Events